This multicohort clinical trial (CHRYSALIS, NCT 02609776) showed that co‐targeting c‐Met and EGFR significantly increased the ORR and durable response, with an ORR of 40% and a median duration of response of 11.1 months.[393] In addition to NSCLC, there is another clinical trial focused on the efficiency and safety of Amivantamab in EGFR‐ or MET‐amplified esophagogastric cancer (NCT05117931). Here, MET is linked to non-small cell lung carcinoma.